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CASE REPORT

Isoniazid Induced Acute Pancreatitis in a Young Girl
Ali Faisal Saleem, Saba Arbab and Farah Qamar Naz

ABSTRACT

Isoniazid (INH) is the mainstay of management against Mycobacterium tuberculosis. INH-induced acute pancreatitis is an
uncommon association and with dearth of literature on it. We are reporting a case of an 11 years old girl who developed
acute pancreatitis after 2 weeks of antituberculous therapy. An INH free regimen was started. She was discharged and
followed without complications.
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INTRODUCTION

Pakistan has high tuberculosis burden. There were more
than two hundred and fifty thousand TB cases reported
from Pakistan in 2010 and 10% of them were of
childhood tuberculosis. Childhood TB is a reflection of
TB control in a population, because it represents the
infectious adult with pulmonary disease that transmit to
the children.1 Isoniazid and rifampicin are the backbone
of TB treatment.

INH is the first line Antituberculous Therapy (ATT) and
was introduced in 1952. It is bactericidal and acts by
inhibiting synthetic pathways of mycolic acid and
metabolized via liver by hepatic N-acetyltransferase.2
INH has infrequent major adverse effects, including
hepatitis, peripheral neuropathy, hypersensitivity reactions (fever, skin eruptions or hematologic alterations
along with lupus-like syndrome that is reversible on
discontinuation of INH.2,3 The most notable adverse
effect is hepatitis. The estimated rate of clinical hepatitis
in patients given INH alone is approximately 0.6%.4

Acute pancreatitis is rarely caused by medications with
an estimated incidence of 0.1 - 2%.5 Isoniazid is a rare
cause of acute pancreatitis,6,7 and rarely reported in
children. We are reporting here a case of young girl
who developed acute pancreatitis within 2 weeks of
her ATT.

She had low grade undocumented fever for 3 weeks and
history of weight loss along with poor appetite and
anorexia prior to this afebrile seizure episodes. Her
father had been treated for pulmonary tuberculosis 4
years back on the basis of radiological grounds only.

Her workup for seizures included normal electrolytes;
Electroencephalogram (EEG) which showed right sided
multifocal spikes and slow waves discharge; and MRIbrain showing bilateral ring enhancing lesions at both
cerebral hemispheres and left cerebellar hemisphere
(Figure 1). Her chest X-ray showed hilar lymphadenopathy. Montoux test was negative. Her ESR was normal.
She was started on first line ATT regimen (isoniazid,
rifampicin, pyrazinamide and ethambutol (mg/kg H10R15Z30E15) along with prednisolone and mucosal
protective agent. She was also started on levetiracetam
after paediatric neurological opinion and discharged
home after a week of admission. She remained well,
seizure free and started gaining weight (800 grams in a
week) in her first week follow-up in the clinic.
Within 2 weeks of discharge, she presented to the
emergency room with severe central abdominal pain
and vomiting without any fever. She denied any urinary

CASE REPORT

An 11 years old girl, weighing 25 kilograms, resident of
Karachi, presented in the emergency room with
generalized tonic clonic seizures for one day. She had
suffered from focal afebrile seizures for the last 4 - 5
days and had received treatment from nearby hospital.

Figure 1: MRI brain showing multiple ring enhancing lesion in bilateral
cerebral hemisphere and left cerebellar hemisphere © (arrow indicate
tuberculomas).
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Figure 2: CT abdomen: Arrows showed significantly swollen pancreas with
peri-pancreatic free fluid.
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complaints and had normal bowel movements.
Remaining aspects of her history were unremarkable.
She was vitally stable with no icterus and skin rashes.
Her abdominal examination revealed epigastric
tenderness without rebound and mild guarding. Rest of
her systemic examination was unremarkable. She was
worked up for acute abdomen. She had normal liver
functions; however, serum amylase was high (2862 IU/L
(normal 25 - 100), serum lipase was 1379 IU/L (normal
28 - 100). Her CT abdomen (Figure 2) showed swollen
head, body and tail of pancreas with signs of acute
pancreatitis. Her ATT and levetiracetam was stopped,
considering drug induced pancreatitis. She was put on
conservative management including nothing per oral
and total parenteral nutrition. Her ATT was temporarily
switched to intravenous rifampicin, levofloxacin,
amikacin and streptomycin (intramuscular) for a week
and she was allowed orally only for medications and her
first line oral ATT was restarted (except INH) gradually.
Within 7 days she was on RZE.
Her laboratory profile was followed 72-hourly that
gradually normalized. Her diet was gradually improved
to soft diet. Her review ultrasound showed resolving
inflammation. After 2 weeks of admission, her enzyme
level became normal and levetiracetam was restarted.
Her serum amylase and lipase were followed twice a
week and no abnormalities were detected. She was
discharged home on RZES (rifampicin, pyrazinamide,
ethambutol and streptomycin) for 2 months along with
levetiracetam with completion of the regimen with RZE
for 10 months. She was followed in the clinic and
remained asymptomatic.

DISCUSSION

INH-induced acute pancreatitis is a rare complication,
that usually occur after within 3 - 4 weeks of therapy and
reversed by withdrawal of the medicine; however the
symptoms recurs with drug re-challenge as reported in
the literature.3,8 This patient developed symptoms within
2 weeks of therapy and her pancreatic enzymes
returned to normal within 2 weeks post-withdrawal of
isoniazid. INH and rifampicin both are associated with
acute pancreatitis,9 but it is extremely rare to have acute
pancreatitis because of rifampicin. There are only few
reported cases of isoniazid induced acute pancreatitis,
but none in children. Identifying cases of isoniazidinduced acute pancreatitis is vital because the development of this condition might be erroneously recognized
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either as an effect of the underlying illness or to some
other medications.3 Correct and early recognition with
prompt drug withdrawal are necessary since drug
induced acute pancreatitis is potentially reversible and
mandates permanent avoidance of isoniazid.7,8 With the
presence of possible confounding effect of rifampicin,
correct recognition of INH-induced acute pancreatitis
becomes even more vital, since it is an essential part of
first line regimen of ATT. The exact mechanism of acute
pancreatitis remains unclear. A dose-dependent manner
on the first encounter or a possibility of a hypersensitivity
syndrome against INH after a re-challenge has been
suggested.3,8,10 Isoniazid toxicity can be prevented by
using therapeutic range and screening of known risk
factors (liver or renal disease). Importantly, INH induced
hepatitis and pancreatitis can be completely recovered if
the drug is withdrawn early.9 A high index of suspicion
and early withdrawal of isoniazid is the key to avoiding
hazardous consequences.
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